Infectious Diseases (all articles)
RCT: Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination.
28 Jan, 2022 | 08:37h | UTCRelated:
WHO issues interim recommendations for heterologous COVID-19 vaccine schedules.
A second version of omicron is spreading. Here’s why scientists are on alert.
28 Jan, 2022 | 08:32h | UTCA second version of omicron is spreading. Here’s why scientists are on alert – NPR
See also: Scientists Watch, Worry About New ‘Stealth’ Version of Omicron Variant – HealthDay
The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life.
28 Jan, 2022 | 08:30h | UTC
Perspective: Will Omicron leave most of us immune?
28 Jan, 2022 | 08:34h | UTCWill Omicron Leave Most of Us Immune? – The Atlantic
They built a smarter approach to Covid clinical trials. Now they want to do the same for other diseases.
28 Jan, 2022 | 08:31h | UTC
Casualties of COVID: Insulin and Dialysis – “How the pandemic has been life-threatening to people living with diabetes and chronic kidney disease”.
28 Jan, 2022 | 08:28h | UTCCasualties of COVID: Insulin and Dialysis - Think Global Health
A nationwide, population-based case-control study showed dentist’s visits were not associated with increased risk of brain abscess.
28 Jan, 2022 | 07:58h | UTCDentist’s visits and risk of brain abscess: a nationwide, population-based case control study – Clinical Infectious Diseases (link to abstract – $ for full-text)
Commentary on Twitter
Finally💥
High-quality large-scale clinical study on brain abscess
Dentist’s visits & risk of brain abscess
Recent invasive dental procedures & number of dentist’s visits were NOT associated w culture verified brain abscess caused by oral cavity bacteria https://t.co/ziEke7eBYm— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) December 30, 2021
Lab study shows new antiviral pills maintain efficacy against Omicron, but antibody drugs are substantially less effective.
27 Jan, 2022 | 10:03h | UTC
Commentary on Twitter
Investigators assessed the in vitro activities of seven monoclonal antibodies & three antiviral drugs against #COVID19 variants. All antibodies showed no or weak neutralizing activity against omicron; two drugs effective at omicron neutralization. https://t.co/rOZzmtsDZS pic.twitter.com/shfKDW6r5q
— NEJM (@NEJM) January 26, 2022
Opinion: Despite Omicron arriving, keeping schools open as safely as possible should be the goal.
27 Jan, 2022 | 09:58h | UTC
Cases of lung transplantation for Covid-19–related respiratory failure in the US were associated with a three-month survival of 95.6%.
27 Jan, 2022 | 10:00h | UTCCommentaries:
New data on COVID-19 lung transplants – Cedars-Sinai Medical Center
~7 Percent of Lung Transplants Due to COVID-19 Respiratory Failure – HealthDay
Omicron’s most crucial warning: A disease can move much faster than we can.
27 Jan, 2022 | 09:57h | UTCOmicron’s most crucial warning: A disease can move much faster than we can – Vox
[Preprint] SARS-CoV-2 Omicron transmission in Danish households.
27 Jan, 2022 | 09:53h | UTCSARS-CoV-2 Omicron VOC Transmission in Danish Households – medRxiv
News Release: Danish researchers investigate Omicron transmission in Danish households – Statens Serum Institut
Commentary on Twitter
Reminder that, despite its infectivity, Omicron's household attack rate is ~1-in-3 (less in fully vaxxed). People often assume that, if one person in household is infected, it's inevitable everybody'll get it. Ain't so; worth trying to isolate if feasible.https://t.co/OLcUtfH8Up
— Bob Wachter (@Bob_Wachter) January 23, 2022
Italian lab study finds Sputnik V beat Pfizer’s mRNA vaccine against Omicron – yielding higher antibody levels.
27 Jan, 2022 | 09:47h | UTC
RCT: Heterologous (Pfizer, J&J, or AstraZeneca) vs. homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil.
26 Jan, 2022 | 02:30h | UTCCommentaries:
Boosting immunity after CoronaVac – The Lancet
Covid-19: CoronaVac immunity is strongest after boosting with a different vaccine – The BMJ
Commentary on Twitter
Heterologous boosting after 2 doses of #CoronaVac COVID-19 vaccine results in more robust immune responses than homologous boosting, study suggests. https://t.co/845JFnn3t7 pic.twitter.com/ibT3b5rs2K
— The Lancet (@TheLancet) January 23, 2022
As Pfizer and BioNTech begin a clinical trial of Omicron-based vaccine, the timeline to authorization is unclear.
26 Jan, 2022 | 02:20h | UTCSee also:
Pfizer begins testing omicron-matched COVID shots in adults – Associated Press
Pfizer and BioNTech start trials of new Omicron-specific jab – BBC
Pfizer and BioNTech begin testing an omicron-specific COVID-19 vaccine – NPR
Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.
26 Jan, 2022 | 02:23h | UTCRelated:
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
Heart-inflammation risk from Pfizer COVID vaccine is very low.
Cohort study: Among patients who survived ICU treatment for COVID-19, 75% still reported physical, mental, or cognitive symptoms after 1 year.
26 Jan, 2022 | 02:28h | UTCCommentaries:
75% of COVID ICU survivors have physical symptoms 1 year on – CIDRAP
Majority of COVID-19 survivors experience health problems one-year post ICU admission – News Medical
Deltacron: the story of the variant that wasn’t.
26 Jan, 2022 | 02:19h | UTCDeltacron: the story of the variant that wasn’t – Nature
Opinion: Preventing SARS-CoV-2 transmission in health care settings in the context of the Omicron variant.
26 Jan, 2022 | 02:14h | UTC
Commentary on Twitter
Our new piece in @JAMA_current
Transmission of #SARSCoV2 in healthcare settings is a serious concern
We outline three ways hospitals can better prepare for surges— mandating boosters, increasing frequency of testing, & upgrading to N95 maskshttps://t.co/2xRKdKPlhO pic.twitter.com/y0L4UzUNSo
— Abraar Karan (@AbraarKaran) January 24, 2022
[Preprint] High prevalence of olfactory disorders 18 months after contracting COVID-19.
26 Jan, 2022 | 02:11h | UTCHigh prevalence of olfactory disorders 18 months after contracting COVID-19 – medRxiv
Commentaries:
Half of first-wave Covid cases may have lasting harm to sense of smell – The Guardian
Prevalence of olfactory dysfunction 18 months after SARS-CoV-2 infection – News Medical
RCT: Electronic directly observed therapy is noninferior to in-person observed therapy for ensuring adherence to tuberculosis treatment.
26 Jan, 2022 | 01:58h | UTC
Commentary on Twitter
In this 2-year study, data showed that electronic directly observed therapy (eDOT) was as effective as traditional in-person DOT for ensuring high adherence to treatment of tuberculosis disease. @CDC_TB @nycHealthy @ColumbiaMed https://t.co/yTrU1JRuwn pic.twitter.com/QXthE4d266
— JAMA Network Open (@JAMANetworkOpen) January 20, 2022
A registry study with 1,581 cases of Stenotrophomonas maltophilia blood and/or lower respiratory infections suggest Levofloxacin is a reasonable alternative to standard therapy with Trimethoprim-sulfamethoxazole.
26 Jan, 2022 | 01:40h | UTC
Commentary on Twitter
A new study in OFID suggests that mortality outcomes are similar comparing levofloxacin and TMP/SMX treatment of S. maltophilia lower respiratory tract and bloodstream infections.
📄:https://t.co/80QDy3DTU9 #IDSAJournals @PaulSaxMD @DrJLi @Keith_S_Kaye @SameerKadri12 pic.twitter.com/TNxQpfT97n
— IDSA (@IDSAInfo) January 23, 2022
Fever of unknown origin and incidence of cancer: a population-based cohort study using nationwide Danish registries showed that cancer risk in one year was 1.2%.
26 Jan, 2022 | 01:36h | UTCFever of unknown origin and incidence of cancer – Clinical Infectious Diseases (link to abstract – $ for full-text)
Systematic Review: Oral antihistamine‐decongestant‐analgesic combinations for the common cold.
26 Jan, 2022 | 01:31h | UTCOral antihistamine‐decongestant‐analgesic combinations for the common cold – Cochrane Library
Commentary: Oral antihistamine-decongestant-analgesic combinations for the common cold – Cochrane Library
Systematic Review: Short intravenous antibiotic courses for urinary infections in young infants.
26 Jan, 2022 | 01:24h | UTCShort Intravenous Antibiotic Courses for Urinary Infections in Young Infants: A Systematic Review – Pediatrics (link to abstract – $ for full-text)